SUTRO BIOPHARMA, INC. Operating Lease, Expense
SUTRO BIOPHARMA, INC. (STRO) reported Operating Lease, Expense of $1.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-12
- SUTRO BIOPHARMA, INC. operating lease, expense for the quarter ending 2026-06-30 was $1.60M, a 20.00% decline year-over-year.
- SUTRO BIOPHARMA, INC. operating lease, expense for the quarter ending 2026-03-31 was $1.60M, a 20.00% decline year-over-year.
- SUTRO BIOPHARMA, INC. operating lease, expense for the quarter ending 2025-12-31 was $1.90M, a 0.00% change year-over-year.
- SUTRO BIOPHARMA, INC. operating lease, expense for the quarter ending 2025-09-30 was $2.00M, a 0.00% change year-over-year.
- SUTRO BIOPHARMA, INC. operating lease, expense for fiscal 2025 was $7.90M, a 0.00% change from fiscal 2024.
- SUTRO BIOPHARMA, INC. operating lease, expense for fiscal 2024 was $7.90M, a 12.86% increase from fiscal 2023.
- SUTRO BIOPHARMA, INC. operating lease, expense for fiscal 2023 was $7.00M, a 12.90% increase from fiscal 2022.
- SUTRO BIOPHARMA, INC. operating lease, expense for fiscal 2022 was $6.20M, a 26.19% decline from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.60M 10-Q · filed 2026-08-12 | $3.10M 10-Q · filed 2026-08-12 | $5.10M derived: sum of 3 quarters · filed 2026-08-12 | $7.10M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.60M 10-Q · filed 2026-05-14 | $3.50M derived: sum of 2 quarters · filed 2026-05-14 | $5.50M derived: sum of 3 quarters · filed 2026-05-14 | $7.50M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $3.90M derived: sum of 2 quarters · filed 2026-03-23 | $5.90M derived: sum of 3 quarters · filed 2026-08-12 | $7.90M 10-K · filed 2026-03-23 |
| 2025-09-30 | $2.00M 10-Q · filed 2025-11-06 | $4.00M derived: sum of 2 quarters · filed 2026-08-12 | $6.00M 10-Q · filed 2025-11-06 | $7.90M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $2.00M 10-Q · filed 2026-08-12 | $4.00M 10-Q · filed 2026-08-12 | $5.90M derived: sum of 3 quarters · filed 2026-08-12 | $7.90M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $2.00M 10-Q · filed 2026-05-14 | $3.90M derived: sum of 2 quarters · filed 2026-05-14 | $5.90M derived: sum of 3 quarters · filed 2026-05-14 | $7.90M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $3.90M derived: sum of 2 quarters · filed 2026-03-23 | $5.90M derived: sum of 3 quarters · filed 2026-03-23 | $7.90M 10-K · filed 2026-03-23 |
| 2024-09-30 | $2.00M 10-Q · filed 2025-11-06 | $4.00M derived: sum of 2 quarters · filed 2025-11-06 | $6.00M 10-Q · filed 2025-11-06 | $7.90M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $2.00M 10-Q · filed 2025-08-07 | $4.00M 10-Q · filed 2025-08-07 | $5.90M derived: sum of 3 quarters · filed 2025-08-07 | $7.90M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $2.00M 10-Q · filed 2025-05-08 | $3.90M derived: sum of 2 quarters · filed 2025-05-08 | $5.90M derived: sum of 3 quarters · filed 2025-05-08 | $7.40M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $3.90M derived: sum of 2 quarters · filed 2025-03-13 | $5.40M derived: sum of 3 quarters · filed 2025-03-13 | $7.00M 10-K · filed 2025-03-13 |
| 2023-09-30 | $2.00M 10-Q · filed 2024-11-13 | $3.50M derived: sum of 2 quarters · filed 2024-11-13 | $5.10M 10-Q · filed 2024-11-13 | $6.60M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $1.50M 10-Q · filed 2024-08-13 | $3.10M 10-Q · filed 2024-08-13 | $4.60M derived: sum of 3 quarters · filed 2025-03-13 | $6.10M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $1.50M 10-Q · filed 2024-05-13 | $3.10M derived: sum of 2 quarters · filed 2025-03-13 | $4.60M derived: sum of 3 quarters · filed 2025-03-13 | $6.10M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $3.10M derived: sum of 2 quarters · filed 2025-03-13 | $4.60M derived: sum of 3 quarters · filed 2025-03-13 | $6.20M 10-K · filed 2025-03-13 |
| 2022-09-30 | $1.50M 10-Q · filed 2023-11-13 | $3.00M derived: sum of 2 quarters · filed 2023-11-13 | $4.60M 10-Q · filed 2023-11-13 | $6.50M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-06-30 | $1.50M 10-Q · filed 2023-08-10 | $3.10M 10-Q · filed 2023-08-10 | $5.00M derived: sum of 3 quarters · filed 2024-03-25 | $7.30M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-03-31 | $1.50M 10-Q · filed 2023-05-15 | $3.50M derived: sum of 2 quarters · filed 2024-03-25 | $5.80M derived: sum of 3 quarters · filed 2024-03-25 | $7.80M derived: sum of 4 quarters · filed 2024-03-25 |
| 2021-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $4.30M derived: sum of 2 quarters · filed 2024-03-25 | $6.30M derived: sum of 3 quarters · filed 2024-03-25 | $8.40M 10-K · filed 2024-03-25 |
| 2021-09-30 | $2.30M 10-Q · filed 2022-11-08 | $4.30M derived: sum of 2 quarters · filed 2022-11-08 | $6.40M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $2.00M 10-Q · filed 2022-08-08 | $4.00M 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $2.00M 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |